Invitae (Invitae) Cash And Cash Equivalents : $158.0 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Invitae Cash And Cash Equivalents?

Invitae's quarterly cash and cash equivalents increased from Mar. 2023 ($161.20 Mil) to Jun. 2023 ($222.76 Mil) but then stayed the same from Jun. 2023 ($222.76 Mil) to Sep. 2023 ($158.01 Mil).

Invitae's annual cash and cash equivalents increased from Dec. 2020 ($124.79 Mil) to Dec. 2021 ($923.25 Mil) but then declined from Dec. 2021 ($923.25 Mil) to Dec. 2022 ($257.49 Mil).

Invitae Cash And Cash Equivalents Historical Data

The historical data trend for Invitae's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invitae Cash And Cash Equivalents Chart

Invitae Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

Get a 7-Day Free Trial

112.16

151.39

124.79

923.25

257.49

Invitae Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash And Cash Equivalents	Get a 7-Day Free Trial															217.03	257.49	161.20	222.76	158.01

Invitae Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Invitae (OTCPK:NVTAQ) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Invitae Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Invitae's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Invitae (Invitae) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitae Corp (OTCPK:NVTAQ) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

NVTA:Mexico IV8:Germany

Address

1400 16th Street, San Francisco, CA, USA, 94103

Website

https://www.invitae.com

Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.

Executives

Ana J. Schrank	officer: Chief Financial Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
Robert M. Guigley	officer: Chief Commercial Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
Robert Iv Dickey	officer: See Remarks	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Jeff Parsons	officer: See remarks	2575 AUGUSTINE DRIVE, SANTA CLARA CA 95054
Robert L Nussbaum	officer: Chief Medical Officer	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Thomas Brida	officer: General Counsel	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Robert F. Werner	officer: Chief Accounting Officer	2500 FABER PLACE, PALO ALTO CA 94303
Yafei Wen	officer: Chief Financial Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
Kenneth D. Knight	officer: Chief Operating Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
William H Osborne	director	1415 WEST 22ND STREET, SUITE 1100, OAK BROOK IL 60523
Sean E George	director, officer: CEO	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Shelly D Guyer	officer: Chief Financial Officer	1025 GREEN STREET, SAN FRANCISCO CA 94133
Katherine Stueland	officer: Chief Commercial Officer	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Geoffrey Crouse	director	3130 GATEWAY DRIVE, P O BOX 5625, NORCROSS GA 30091-5625
Jason W. Myers	director, other: President, Oncology	C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301